PharmaCanada - Lung Cancer & Early Cancer Detection

8/3/2019 PharmaCanada - Lung Cancer & Early Cancer Detection

http://slidepdf.com/reader/full/pharmacanada-lung-cancer-early-cancer-detection 1/12

www.earlycancerdetect.com



According to the World Health Organization (WHO)International Agency for Research on Cancer, LungCancer is the globallyaccounting

. In the , studiesshowed that

, having the lowest survival rate at 15%.

Over the last 30 years, doctors have greatly improved the survival rates for manytypes of cancer. Sadly, Lung Cancer survival rates is the Same and remain one of the top cancer sites. Aggressive but silent,

, since the tumor

is already in its advance stage.

Today, there is hope in improving the chances for survival through early cancerdetection, now available in the Philippines.



Cigarette smoking is the primary risk factor for lung cancer and85% of all lung cancer cases are caused by cigarette smoking.An individual’s risk for developing Lung Cancer depends on how

much they’ve smoked, the age at which they started smoking,and the age at which they quit.

For non-smokers, second-hand smoke is the main cause of lungcancer, but other risk factors include : exposure to industrial orenvironmental carcinogens such as asbestos and radon; and lungdisease, especially diseases which scar or damage the lungs. Therisk of developing lung cancer also increases with age andheredity.



In the past, if you were worried about having lung cancer, there was nosimple test to take. Most patients even high-risk ones were not tested forlung cancer until they showed symptoms of the disease. By then, if lungcancer was present, it was usually too late.

Fortunately, times have changed. Pharmacanada’s early lung cancerdetection test has been designed to check for early-stage lung cancer in

high-risk individuals who:◦ Are over 40 years old◦ Have had significant exposure to: Cigarette smoke (one pack a day for 20 years)

and industrial carcinogens

◦ Have symptoms such as persistent cough or shortness of breath or other indicatorslike suspicious radiography

The technology for early cancer detection was produced by research at the

British Columbia Cancer Agency. It has been established through a multi-centered validation trial which demonstrated that fully automated DNAanalysis of sputum cells using ClearCyte™ detects early stage, pre-symptomatic or stage 1 lung cancer before it is discernable by standard x-ray or CT scan imaging.



When it comes to lung cancer, early detection is the key in extending thelives and improving the quality of life for those who have the disease.

The innovative technology of ClearCyte™ brings new hope to the battle. Itis safe, simple, and a non-invasive test for early detection of lung cancer.By analyzing the lung cells commonly found in sputum, the test can detect

cancer before it spreads, increasing the likelihood of successful treatment.

Similar to Papsmear Test for cervical cancer or the Prostate Specific Antigen(PSA) test for prostate cancer, the ClearCyte™ does not provide a “yes orno” diagnosis but it rather indicates the likelihood that an individual haslung cancer.

Although not a diagnostic test, the existence of a likelihood predictor suchas ClearCyte™ is of enormous value in the fight against lung cancer.



The Early Cancer Detection (ECD) test kit provided by Pharmacanada can be used

with a number of tools to help obtain the sputum sample necessary for analysis:

Lung flute

Medication

Expectorants

Nebulizers

Producing a sputum sample using the Pharmacanada kit causes very little

physical discomfort. Almost anyone can use the kit, with the following

Patients who have had thoracic and cardiac surgery within the last 6 months

Patients with asthma or COPD exacerbation in the last 5 days

Patients with flu-like symptoms such as fever or chills



ECD test similar to Papsmear test for cervical cancer or the Prostate

Specific Antigen (PSA) test for prostate cancer does not provide a “yes

or no” answer to the question : “Do I have lung cancer?”. Instead, ECD

results are presented as a “risk multiplier”, indicating the statistical

likelihood that an individual harbors lungs cancer. ECD test provides an

automated analysis of properties of epithelial cells present in sputum

specimen. The test measures property of cell nuclei such as DNA

content, conformation and texture. It identifies possible malignant cells

as well as changes in normal appearing cell nuclei that are associated

with the presence of malignancy.



Sputum samples are sent to Pharmacanada’s cytology laboratory at St.Dominic Medical Center in Cavite City for analysis. Reports are typicallysent to the requesting physician through email within 10 working daysof sample receipt by the laboratory,

ECD scores should be interpreted in context to an individual’s overall

health and medical history. Therefore, ECD results are sent to yourdoctor, who has the expertise necessary to interpret them andrecommend any further action.

Although not a diagnostic test. People need not wait for signs andsymptoms of the disease to manifest before taking the test. Theexistence of a likelihood predictor such as the ECD provided byPharmacanada is potentially of enormous value in the fight against lungcancer.





If you would like to take the Early CancerDetection (ECD) test provided byPharmacanada, talk with your doctor aboutyour risk of lung cancer, and how ECD isright for you.



Early Cancer Detection (ECD) test

Call : (632) 553-4276, (632) 553-4205 Visit: Pharmacanada Inc.

Penthouse 4, VGP Center, 6772Ayala Ave., Makati City Philippines

E-mail: [email protected] Website: www.earlycancerdetect.com

Test available at select medical and diagnostic centres.

mailto:[email protected]

http://www.earlycancerdetect.com/

http://www.earlycancerdetect.com/

mailto:[email protected]



Early Cancer Detection Provider

THANK YOU

Documents

PharmaCanada - Lung Cancer & Early Cancer Detection